If you are looking for big returns and have a high tolerance for risk, then read on.

That’s because listed below is one ASX share that Bell Potter believes could rocket higher over the next 12 months.

Which ASX All Ords share?

The share that has caught the eye of Bell Potter is Aroa Biosurgery Ltd (ASX: ARX).

It is a commercial stage medical device company that operates within the wound care and soft tissue reconstruction sector.

Bell Potter was pleased to see that the company has successfully completed a prospective randomised controlled trial for Symphony in diabetic foot ulcers.

It highlights that the “preliminary results [are] indicating the primary endpoint of complete wound closure at 12 weeks was met.”

This is good news because the Symphony product could have a billion-dollar market opportunity. It commented:

Although the full dataset remains due in Q3 FY27, the readout provides important clinical validation ahead of Symphony’s commercial launch and supports its positioning under a tougher coverage framework. That early validation arrives as the CY26 CMS reimbursement reset continues to disrupt the US skin substitute market. 

The new US$127.14/cm² flat rate has compressed the elevated pricing underpinning many legacy products, with Organogenesis and MiMedx both reporting wound-care revenue declines of at least 60% in Q1 CY26 and consensus expecting pressure to persist through the year. We estimate market size in outpatient care at greater than US$1b.

Time to buy

According to the note, the broker has retained its buy rating and $1.09 price target on the ASX All Ords share. Based on its current share price of 58.5 cents, this implies potential upside of 86% for investors over the next 12 months.

Touching on its outlook and investment thesis, Bell Potter said:

Beyond the clinical readouts, 2H CY26 should bring further clarity on the reimbursement environment. Key watchpoints should include the final PFS and OPPS rules following CMS’s proposal to retain the current flat-rate methodology for CY27, while any revised DFU/VLU LCDs could further raise the evidence threshold and narrow the reimbursable product set. 

Investment thesis: Buy; TP $1.09 (unchanged) The Myriad growth story remains intact and the outlook for Symphony revenues continues to improve. We make no changes to earnings and maintain our Buy rating and PT of $1.09.

This could make Aroa Biosurgery worth considering if you are looking for exposure to the healthcare sector.

The post Which ASX All Ords share could rocket 90%? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Age Pension is a fortnightly sum paid to Australians aged 67 years or older to help them fund a basic retirement.

The catch is, not everyone over 67 years old is eligible. And the payment amount you could get is heavily dependent on your income and the value of assets you own.

Here’s everything you need to know about the Age Pension income test, the asset test, and how much you could get.

The maximum Age Pension payment

The Age Pension has a maximum total fortnightly payment of $1,200.90 for retired singles and $1,810.40 for couples combined. 

These sums include the maximum basic rate, the maximum pension supplement, and the energy supplement.

How is my final payment level calculated?

Centrelink assesses you under both an income and an asset test. It then applies whichever gives you the lowest rate of payment for your individual circumstances.

What is the Age Pension income test?

The income test assesses all of your income, pooled from all sources.

Your income includes your wages, but also includes anything from superannuation contributions, investment income, bonuses, or commission payments. 

It’s also applicable regardless of your age. 

In order to receive the full Age Pension single Australians can earn up to $226 per fortnight. Meanwhile, couples can earn up to $396 per fortnight.

But the good news is that if you’re over these thresholds, you could still be eligible for some sort of part payment. 

Single Australians can earn up to $2,627.80 per fortnight. Then and couples (living together) can earn up to $4,016.80 per fortnight and still qualify for at least a part-Age Pension, which is assessed on a sliding scale.

For a single person, your Age Pension will reduce by 50 cents for each dollar over $226. For couples it will reduce by 25 cents for each dollar over $396.

It means that the more you earn, the lower your Age Pension payment will be, until it reaches zero.

What about the Age Pension asset test?

The asset test includes everything you own, whether it’s in full, in part, or you have an interest in. It does exclude your primary residence. 

In order to receive the full Age Pension, single homeowners cannot own assets valued at $333,000 or more. For non-homeowners, this will be up to $600,000.

Meanwhile, a couple (combined) can own up to $499,000 in value if they own a property, or $766,000 if they don’t.

Again, as with the income test, if you’re over these thresholds, it’s still possible to get some sort of partial payment.

Single Australians who are homeowners can own assets valued up to $733,500, and single non-homeowners can own assets valued up to $1,000,500, and still be eligible for some level of part-payment.

Couples are also entitled to a partial payment, provided their combined assets don’t exceed $1,102,500 for homeowners. Non-homeowners can own assets totalling no more than $1,369,500.

The post Australian Age Pension: Income test, assets test and payment amounts explained appeared first on The Motley Fool Australia.

More reading

• Here’s what $10,000 invested in ASX tech shares 5 years ago would be worth now
• 4 ASX shares which could improve by 25% to more than 100%
• Which ASX All Ords share could rocket 90%?
• 2 ASX small-caps with 40% upside
• 3 of the best ASX dividend stocks to supplement your superannuation

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX small caps can offer strong growth prospects to an investor’s portfolio. 

With global headwinds impacting the ASX 200 this year, it could be an ideal time to allocate capital towards high upside stocks. 

The team at Bell Potter have identified two in particular that fit this criteria. 

Let’s see what the broker is projecting. 

Orthocell Ltd (ASX: OCC)

Orthocell is an Australian-based, commercial-stage regenerative medicine company developing and commercialising collagen-based medical devices and autologous cell therapies for the repair and regeneration of bone and soft tissue.

The company leverages their proprietary collagen processing and manufacturing platform to produce implantable biomaterials designed to support tissue regeneration and functional recovery.

As is commonplace with small-cap shares, it has experienced some volatility in 2026. 

However, Bell Potter has a speculative buy rating on this ASX small-cap, suggesting it could rise by 40% in the next year. 

In a note released yesterday, Bell Potter said June-quarter revenue increased 19% QoQ to a record $3.8m (+36% pcp), reflecting continued strength across the established market.

The broker said the US rollout of Remplir is making good progress. 

The product is now available to around half of the US population through expanded distributor coverage. 

Hospital access is also growing, with approvals in 151 hospitals and more applications still under review. 

In simple terms, more hospitals are buying the company’s nerve repair product Remplir, and more surgeons have started using it. 

However, sales growth has trailed hospital access growth, suggesting many surgeons are still trialling the product and are yet to commit.

Based on this guidance, Bell Potter has a 12-month price target of $1.19 on this ASX small-cap, indicating a 40% upside from current levels. 

Sky Metals Ltd (ASX: SKY)

Another ASX small-cap drawing a speculative buy rating is Sky Metals. 

Sky Metals engages in the acquisition, exploration, and development of mineral resources.

Its share price has rocketed 183% higher year to date, and Bell Potter believes the growth can continue. 

Bell Potter noted that Sky Metals has significantly increased the estimated size of its Tallebung project in New South Wales. 

The updated resource now contains much more tin and tungsten than previously estimated. The company has also identified its first silver resource. 

Much of the resource is now classified with higher confidence, making it more likely to be converted into mineable reserves.

Based on this guidance, the broker has placed a 12-month price target of $0.350 on this ASX small-cap, indicating 37% upside from current levels. 

The post 2 ASX small-caps with 40% upside appeared first on The Motley Fool Australia.

More reading

• Is this ASX consumer discretionary stock a buy after jumping 10% yesterday?
• Top broker tips 37% upside for this exciting ASX healthcare stock
• Broker tips 20% and 23% upside for these 2 ASX stocks
• Amplitude Energy shares could be set to soar 90%: Expert
• What is Bell Potter saying about A2 Milk shares after its results?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.